-
Choosing depot medroxyprogesterone acetate (DMPA, Depo Provera, Pfizer, New York City) may free women from taking a daily pill, but they must return to providers' offices for quarterly injections. What if pharmacists could administer repeat injections?
-
Nurse practitioners, physician assistants, and certified nurse-midwives provide many health services in family planning, yet many of their training programs do not provide didactic or clinical education about abortion services, results from a recently published survey show.
-
Results from a recently published study suggest that combination oral contraceptives (OCs) and oral medroxyprogesterone acetate (MPA) may be effective treatment options for acute uterine bleeding.
-
Rewind to 1997: President Clinton announces a 10-year goal for the development of an HIV/ AIDS vaccine. Fast forward to 2007. Are you able to provide such a vaccine to your patients?
-
What if you could offer your patients emergency contraception (EC) in a single tablet with one-time dosing? Scientists are looking at CDB-2914, a new progesterone receptor modulator (PRM), that may provide EC in such a dosing regimen.
-
For the most current information on breastfeeding for new mothers, take a look at GotMom.org, a newly-revamped site sponsored by the American College of Nurse-Midwives (ACNM) and Avent, a manufacturer of infant and toddler feeding products.
-
Results of a new study indicate that providing women with an advance supply of oral contraceptives (OCs) results in fewer gaps in usage, longer-term contraceptive use, and less expense to health care providers and patients when compared with prescriptions that require multiple office visits or refills.
-
Searching Google yielded a correct diagnosis in greater than half of cases.
-
The Finnish Diabetes Prevention Study (FDPS) demonstrated that a program of diet and exercise was capable of reducing the incidence of diabetes by approximately 60% in persons with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), compared to placebo.
-
The FDA has approved a new atypical antipsychotic agent. Paliperidone is the active metabolite of risperidone. The drug is formulated in an osmotic drug delivery system (OROS) developed by ALZA.